The SELECT cardiovascular outcomes trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% (HR 0.80, 95% CI: 0.72 to 0.90) compared to placebo over a median 39.8 months of follow-up (Lincoff et al., NEJM, 2023) [14]
(12) The Food and Drug Administration in the Philippines - where the practice is incredibly popular - has also warned against IV glutathione, warning of potential liver damage, allergic reactions and a lack of standard dosing
You must be enrolled in a standalone Medicare Part D prescription drug plan or a Medicare Advantage plan that includes drug coverage
PMID: 28533317 Albano GD, et al
Translation: it may not be the weight loss alone that's to blame for your sagging
So much of whats out there and part of our diets is processed foods, McRae says